Futura Medical plc (FAMDF) Research
Futura Medical plc is a pharmaceutical company that formulates and brings to market healthcare solutions and medicines for the consumer sector, primarily concentrating on sexual well-being and managing discomfort. Their flagship product, MED3000, is a topical gel specifically developed to address erectile dysfunction. The company's pipeline also encompasses a range of pain relief treatments, featuring TPR100, a topical diclofenac gel; CBD100, a topical cannabidiol preparation; and TIB200, a topical ibuprofen gel. Established in 2001, Futura Medical plc operates from its headquarters located in Guildford, United Kingdom.
Market snapshot
- Symbol
- FAMDF
- Price
- $0.01
- Day change
- -76.67%
- Market cap
- $1.8M
- P/E ratio
- -0.35x
- 52-week range
- 0.0013-0.2
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 3 months
Recent news
- Microsoft Q3 results top expectations, driven by Intelligent Cloud strength
Microsoft Corp (NASDAQ:MSFT) reported fiscal third quarter earnings that exceeded Wall Street expectations, driven by continued strength in its cloud and...
- Futura Medical refines strategy and evolves commercial model after tough 2025
Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX), the consumer healthcare company behind erectile dysfunction gel Eroxon, said it has refined its strategy...
- Gold just had one of its worst weeks in 40 years. Is it time to buy the dip?
The metal dropped 17% in five trading days, briefly erasing all of its 2026 gains. The sell-off looks dramatic. The case for holding is stronger than it...
Peer companies
Open Futura Medical plc (FAMDF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.